These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 18270864)
21. B-cell depletion in the treatment of mixed cryoglobulinemia. Sansonno D; Tucci FA; Montrone M; Troiani L; Sansonno L; Gatti P; Lauletta G Dig Liver Dis; 2007 Sep; 39 Suppl 1():S116-21. PubMed ID: 17936212 [TBL] [Abstract][Full Text] [Related]
22. The challenge of treating hepatitis C virus-associated cryoglobulinemic vasculitis in the era of anti-CD20 monoclonal antibodies and direct antiviral agents. Roccatello D; Sciascia S; Rossi D; Solfietti L; Fenoglio R; Menegatti E; Baldovino S Oncotarget; 2017 Jun; 8(25):41764-41777. PubMed ID: 28454112 [TBL] [Abstract][Full Text] [Related]
23. Health-related quality of life in severe cryoglobulinaemic vasculitis and improvement after B-cell depleting therapy. Quartuccio L; Isola M; Masolini P; Scaini P; Zani R; Tavoni A; Pietrogrande M; Bombardieri S; De Vita S Clin Exp Rheumatol; 2013; 31(1 Suppl 75):S9-14. PubMed ID: 23044040 [TBL] [Abstract][Full Text] [Related]
24. Rituximab may form a complex with IgMkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis. Sène D; Ghillani-Dalbin P; Amoura Z; Musset L; Cacoub P Arthritis Rheum; 2009 Dec; 60(12):3848-55. PubMed ID: 19950292 [TBL] [Abstract][Full Text] [Related]
25. Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. Petrarca A; Rigacci L; Caini P; Colagrande S; Romagnoli P; Vizzutti F; Arena U; Giannini C; Monti M; Montalto P; Matucci-Cerinic M; Bosi A; Laffi G; Zignego AL Blood; 2010 Jul; 116(3):335-42. PubMed ID: 20308604 [TBL] [Abstract][Full Text] [Related]
26. Cryoglobulinaemia type III with severe neuropathy and immune complex glomerulonephritis: remission after plasmapheresis and rituximab. Braun A; Neumann T; Oelzner P; Hein G; Gröne HJ; Ziemer M; Wolf G Rheumatol Int; 2008 Mar; 28(5):503-6. PubMed ID: 17924113 [TBL] [Abstract][Full Text] [Related]
27. How HCV has changed the approach to mixed cryoglobulinemia. Della Rossa A; Baldini C; Tavoni A; Bombardieri S Clin Exp Rheumatol; 2009; 27(1 Suppl 52):S115-23. PubMed ID: 19646357 [TBL] [Abstract][Full Text] [Related]
28. Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry. Terrier B; Launay D; Kaplanski G; Hot A; Larroche C; Cathébras P; Combe B; de Jaureguiberry JP; Meyer O; Schaeverbeke T; Somogyi A; Tricot L; Zénone T; Ravaud P; Gottenberg JE; Mariette X; Cacoub P Arthritis Care Res (Hoboken); 2010 Dec; 62(12):1787-95. PubMed ID: 20740617 [TBL] [Abstract][Full Text] [Related]
29. Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. Saadoun D; Resche Rigon M; Sene D; Terrier B; Karras A; Perard L; Schoindre Y; Coppéré B; Blanc F; Musset L; Piette JC; Rosenzwajg M; Cacoub P Blood; 2010 Jul; 116(3):326-34; quiz 504-5. PubMed ID: 20439619 [TBL] [Abstract][Full Text] [Related]
30. Rituximab in cryoglobulinaemic vasculitis, evidence for its effectivity: a case report and review of literature. Wink F; Houtman PM; Jansen TL Clin Rheumatol; 2011 Feb; 30(2):293-300. PubMed ID: 21053035 [TBL] [Abstract][Full Text] [Related]
31. Rituximab plus belimumab in non-infectious refractory cryoglobulinemia vasculitis: A pilot study. Saadoun D; Ghembaza A; Riviere S; Mekinian A; Boutemy J; Leroux G; Domont F; Maillard H; Vautier M; Cacoub P J Autoimmun; 2021 Jan; 116():102577. PubMed ID: 33248866 [TBL] [Abstract][Full Text] [Related]
37. The use of monoclonal antibody (rituximab) in the treatment of type II mixed cryoglobulinemia. Rego TC; Massumoto CM; Batista RS; Moura LH; Soares LM; Gomes AP Braz J Infect Dis; 2007 Feb; 11(1):174-5. PubMed ID: 17625752 [TBL] [Abstract][Full Text] [Related]
38. [Monoclonal antibodies to B-lymphocytes (rituximab) in the treatment of HCV-associated severe cryoglobulinemic glomerulonephritis]. Milovanova SIu; Lopatkina TN; Kozlovskaia LV; Krasnova TN Ter Arkh; 2007; 79(6):69-72. PubMed ID: 17684972 [No Abstract] [Full Text] [Related]
39. Acute wrist and foot drop associated with hepatitis C virus related mixed cryoglobulinemia: rapid response to treatment with rituximab. Uppal R; Charles E; Lake-Bakaar G J Clin Virol; 2010 Jan; 47(1):69-71. PubMed ID: 19892591 [TBL] [Abstract][Full Text] [Related]
40. Clinical and morphologic spectrum of renal involvement in patients with mixed cryoglobulinemia without evidence of hepatitis C virus infection. Matignon M; Cacoub P; Colombat M; Saadoun D; Brocheriou I; Mougenot B; Roudot-Thoraval F; Vanhille P; Moranne O; Hachulla E; Hatron PY; Fermand JP; Fakhouri F; Ronco P; Plaisier E; Grimbert P Medicine (Baltimore); 2009 Nov; 88(6):341-348. PubMed ID: 19910748 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]